Markers of the Inflammatory Response (IL-1β, IL-10, IL-17A and TNF-α) in Patients With Colorectal Cancer in Chemotherapy Supplemented With Fish Oil
The study will recruit patients with newly diagnosed colorectal cancer and that has not yet
undergone any chemotherapy treatment. Individuals that meet the inclusion criteria are
randomized by means of a computer program on two study groups: 1) supplemented Experimental:
receive 2g/day supplementation encapsulated fish oil for 9 weeks. 2) No intervention -
control: not receive supplementation of fish oil or placebo. Will be assessed the effects of
supplementation on the standard profile of cytokine production, nutritional status, and
proportion of incorporation of these fatty acids in blood cells (mononuclear and red blood
Blood samples are collected before the start of first chemotherapy and nine weeks later.
Supplementation in the experimental group also will start on the first day of chemotherapy.
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
change in inflammatory markers
will be evaluated cytokines IL-1 beta, IL-10, IL-17A and TNF alpha, and acute phase proteins CRP and Albumin, in baseline that corresponds to the day that the patient will begin chemotherapy and the final moment, which corresponds to 9 weeks counting from the baseline in both groups (supplemented and non-supplemented)
Michel C Mocellin, Master's
Universidade Federal de Santa Catarina
Brazil: National Health Surveillance Agency